Future alternative therapies for β-thalassemia

References

• Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge University Press, Cambridge, UK (2001).
   Google Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood104(1), 34–39 (2004).
   PubMed Web of Science ®Google Scholar
• Cao A, Pintus L, Lecca U et al. Control of homozygous β-thalassemia by carrier screening and antenatal diagnosis in sardinians. Clin. Genet.26(1), 12–22 (1984).
   PubMedGoogle Scholar
• Vichinsky EP. Changing patterns of thalassemia worldwide. Ann. NY Acad. Sci.1054, 18–24 (2005).
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Xu J, Ragoczy T et al. Developmental and species-divergent globin switching are driven by bcl11a. Nature460(7259), 1093–1097 (2009).
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Menne TF, Xu J et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor bcl11a. Science322, 1839–1842 (2008).
   PubMed Web of Science ®Google Scholar
• Lettre G, Sankaran VG, Bezerra MA et al. DNA polymorphisms at the bcl11a, hbs1l-myb, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc. Natl Acad. Sci. USA105(33), 11869–11874 (2008).
   PubMed Web of Science ®Google Scholar
• Uda M, Galanello R, Sanna S et al. Genome-wide association study shows bcl11a associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc. Natl Acad. Sci. USA105(5), 1620–1625 (2008).
   PubMed Web of Science ®Google Scholar
• Wahlberg K, Jiang J, Rooks H et al. The hbs1l-myb intergenic interval associated with elevated hbf levels shows characteristics of a distal regulatory region in erythroid cells. Blood114(6), 1254–1262 (2009).
   PubMed Web of Science ®Google Scholar
• Menzel S, Thein SL. Genetic architecture of hemoglobin F control. Curr. Opin. Hematol.16(3), 179–186 (2009).
   PubMed Web of Science ®Google Scholar
• Creary LE, Ulug P, Menzel S et al. Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and hbf levels in sickle cell patients. PLoS ONE4(1), E4218 (2009).
   PubMed Web of Science ®Google Scholar
• Gambari R, Fibach E. Medicinal chemistry of fetal hemoglobin inducers for treatment of β-thalassemia. Curr. Med. Chem.14(2), 199–212 (2007).
   PubMed Web of Science ®Google Scholar
• Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid bfu-e and cfu-e progenitors does not require erythropoietin or the erythropoietin receptor. Cell83(1), 59–67 (1995).
   PubMed Web of Science ®Google Scholar
• D’andrea A, Fasman G, Wong G, Lodish H. Erythropoietin receptor: Cloning strategy and structural features. Int. J. Cell Cloning8(Suppl. 1), 173–180 (1990).
   PubMedGoogle Scholar
• D’andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell57(2), 277–285 (1989).
   PubMed Web of Science ®Google Scholar
• Li K, Miller C, Hegde S, Wojchowski D. Roles for an epo receptor tyr-343 stat5 pathway in proliferative co-signaling with kit. J. Biol. Chem.278(42), 40702–40709 (2003).
   PubMedGoogle Scholar
• Menon MP, Fang J, Wojchowski DM. Core erythropoietin receptor signals for late erythroblast development. Blood107(7), 2662–2672 (2006).
   PubMed Web of Science ®Google Scholar
• Menon MP, Karur V, Bogacheva O, Bogachev O, Cuetara B, Wojchowski DM. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-stat5 axis. J. Clin. Invest.116(3), 683–694 (2006).
   PubMed Web of Science ®Google Scholar
• Von Lindern M, Zauner W, Mellitzer G et al. The glucocorticoid receptor cooperates with the erythropoietin receptor and c-kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood94(2), 550–559 (1999).
   PubMedGoogle Scholar
• Dolznig H, Grebien F, Deiner EM et al. Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of epor, stat5 and the gr. Oncogene25(20), 2890–2900 (2006).
   PubMedGoogle Scholar
• Hoelbl A, Kovacic B, Kerenyi MA et al. Clarifying the role of stat5 in lymphoid development and abelson-induced transformation. Blood107(12), 4898–4906 (2006).
   PubMedGoogle Scholar
• Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in stat5a-/-5b-/- mice due to decreased survival of early erythroblasts. Blood98(12), 3261–3273 (2001).
   PubMed Web of Science ®Google Scholar
• Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in stat5a-/-5b-/- mice: a direct role for stat5 in bcl-x(l) induction. Cell98(2), 181–191 (1999).
   PubMed Web of Science ®Google Scholar
• Kerenyi MA, Grebien F, Gehart H et al. Stat5 regulates cellular iron uptake of erythroid cells via irp-2 and tfr-1. Blood112(9), 3878–3888 (2008).
   PubMedGoogle Scholar
• Libani IV, Guy EC, Melchiori L et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia. Blood112(3), 875–885 (2008).
   PubMed Web of Science ®Google Scholar
• Rivella S. Ineffective erythropoiesis and thalassemias. Curr. Opin. Hematol.16(3), 187–194 (2009).
   PubMed Web of Science ®Google Scholar
• Wang YL, Vandris K, Jones A et al. Jak2 mutations are present in all cases of polycythemia vera. Leukemia22(6), 1289 (2007).
   PubMedGoogle Scholar
• De Domenico I, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with jak2. Proc. Natl Acad. Sci. USA106(10), 3800–3805 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab.9(5), 461–473 (2009).
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, Langelier C et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol. Biol. Cell.18(7), 2569–2578 (2007).
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Pattoneri P. Oral iron chelators. Annu. Rev. Med.60, 25–38 (2009).
   PubMed Web of Science ®Google Scholar
• Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood88(2), 705–713 (1996).
   PubMed Web of Science ®Google Scholar
• Shinar E, Rachmilewitz EA. Oxidative denaturation of red blood cells in thalassemia. Semin. Hematol.27(1), 70–82 (1990).
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P et al. Survival and complications in thalassemia. Ann. NY Acad. Sci.1054, 40–47 (2005).
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, Macmillan JH et al. Survival in medically treated patients with homozygous β-thalassemia. N. Engl. J. Med.331(9), 574–578 (1994).
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica89(10), 1187–1193 (2004).
   PubMed Web of Science ®Google Scholar
• Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: an optimistic update. Semin. Hematol.38(4), 360–366 (2001).
   PubMed Web of Science ®Google Scholar
• Zanninelli G, Breuer W, Cabantchik ZI. Labile plasma iron (lpi), as an indicator of individual daily efficacy of chelation therapy in TM patients. Br. J. Hematol (2009) (In press).
   PubMedGoogle Scholar
• Ganz T. The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease. Isr. Med. Assoc. J.4(11), 1043–1045 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science306(5704), 2090–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (usf2) knockout mice. Proc. Natl Acad. Sci. USA98(15), 8780–8785 (2001).
   PubMed Web of Science ®Google Scholar
• Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc. Natl Acad. Sci. USA98(15), 8160–8162 (2001).
   PubMed Web of Science ®Google Scholar
• Nicolas G, Bennoun M, Porteu A et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl Acad. Sci. USA99(7), 4596–4601 (2002).
   PubMed Web of Science ®Google Scholar
• Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest.110(7), 1037–1044 (2002).
   PubMed Web of Science ®Google Scholar
• Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem.276(11), 7806–7810 (2001).
   PubMed Web of Science ®Google Scholar
• Pigeon C, Ilyin G, Courselaud B et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem.276(11), 7811–7819 (2001).
   PubMed Web of Science ®Google Scholar
• Rechavi G, Rivella S. Regulation of iron absorption in hemoglobinopathies. Curr. Mol. Med.8(7), 646–662 (2008).
   PubMedGoogle Scholar
• Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu. Rev. Pathol.4, 489–515 (2009).
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Weatherall DJ. Clinical aspects of β-thalassemia. In: Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge University Press, Cambridge, UK (2001).
   Google Scholar
• Hershko C, Rachmilewitz EA. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Br. J. Haematol.42(1), 125–132 (1979).
   PubMedGoogle Scholar
• Kattamis A, Papassotiriou I, Palaiologou D et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica91(6), 809–812 (2006).
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Ganz T et al. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica92(5), 583–588 (2007).
   PubMed Web of Science ®Google Scholar
• Adamsky K, Weizer O, Amariglio N et al. Decreased hepcidin mRNA expression in thalassemic mice. Br. J. Haematol.124(1), 123–124 (2004).
   PubMed Web of Science ®Google Scholar
• Weizer O, Adamsky K, Breda L et al. Hepcidin expression in cultured liver cells responds differently to iron overloaded sera derived from patients with thalassemia and hemochromatosis. Blood (ASH Annual Meeting Abstracts)104, (2004) (Abstract 3196).
   Google Scholar
• Weizer-Stern O, Adamsky K, Amariglio N et al. mRNA expression of iron regulatory genes in β-thalassemia intermedia and β-thalassemia major mouse models. Am. J. Hematol.81(7), 479–483 (2006).
   PubMed Web of Science ®Google Scholar
• Erlandson ME, Walden B, Stern G, Hilgartner MW, Wehman J, Smith CH. Studies on congenital hemolytic syndromes, iv. gastrointestinal absorption of iron. Blood19, 359–378 (1962).
   PubMed Web of Science ®Google Scholar
• Gardenghi S, Marongiu MF, Ramos P et al. Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood109(11), 5027–5035 (2007).
   PubMed Web of Science ®Google Scholar
• Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis.29(3), 327–335 (2002).
   PubMed Web of Science ®Google Scholar
• Vokurka M, Necas E. Hepcidin – a peptide regulating the quantity and distribution of iron in the body in healthy and disease states. Cas. Lek. Cesk.142(8), 465–469 (2003).
   PubMedGoogle Scholar
• Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood108(12), 3730–3735 (2006).
   PubMed Web of Science ®Google Scholar
• Tanno T, Porayette P, Sripichai O et al. Identification of twsg1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood114(1), 181–186 (2009).
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, Oneal PA et al. High levels of gdf15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med.13(9), 1096–1101 (2007).
   PubMed Web of Science ®Google Scholar
• Kanda J, Mizumoto C, Kawabata H et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica93(10), 1550–1554 (2008).
   PubMed Web of Science ®Google Scholar
• Ramirez JM, Schaad O, Durual S et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br. J. Haematol.144(2), 251–262 (2009).
   PubMed Web of Science ®Google Scholar
• Yoon D, Pastore YD, Divoky V et al. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J. Biol. Chem.281(35), 25703–25711 (2006).
   PubMed Web of Science ®Google Scholar
• Peyssonnaux C, Zinkernagel AS, Schuepbach RA et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (hifs). J. Clin. Invest.117(7), 1926–1932 (2007).
   PubMed Web of Science ®Google Scholar
• Pinto JP, Ribeiro S, Pontes H et al. Erythropoietin mediates hepcidin expression in hepatocytes through epor signalling and regulation of c/ebp{α}. Blood111(12), 5727–5733 (2008).
   PubMed Web of Science ®Google Scholar
• Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. Hif-2α, but not hif-1α, promotes iron absorption in mice. J. Clin. Invest.119(5), 1159–1166 (2009).
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Daraio F, Filippini A et al. Liver expression of hepcidin and other iron genes in two mouse models of β-thalassemia. Haematologica91(10), 1336–1342 (2006).
   PubMed Web of Science ®Google Scholar
• Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood99(1), 36–43 (2002).
   PubMed Web of Science ®Google Scholar
• Prus E, Fibach E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A73(1), 22–27 (2008).
   PubMed Web of Science ®Google Scholar
• Kuypers FA, Yuan J, Lewis RA et al. Membrane phospholipid asymmetry in human thalassemia. Blood91(8), 3044–3051 (1998).
   PubMed Web of Science ®Google Scholar
• Ruf A, Pick M, Deutsch V et al.In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β-thalassaemia major. Br. J. Haematol.98(1), 51–56 (1997).
   PubMed Web of Science ®Google Scholar
• Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting c/ebpa and stat-3. Biochem. Biophys. Res. Commun.356(1), 312–317 (2007).
   PubMedGoogle Scholar
• Goldschmidt N, Spectre G, Brill A et al. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb. Haemost.100(5), 864–870 (2008).
   PubMed Web of Science ®Google Scholar
• Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. Padgem/gmp-140 expression on platelet membranes from homozygous β thalassaemic patients. Br. J. Haematol.84(1), 111–117 (1993).
   PubMed Web of Science ®Google Scholar
• Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of β-thalassaemic erythrocytes to endothelial cells. Br. J. Haematol.106(1), 178–181 (1999).
   PubMed Web of Science ®Google Scholar
• Shirahata A, Funahara Y, Opartkiattikul N, Fucharoen S, Laosombat V, Yamada K. Protein c and protein s deficiency in thalassemic patients. Southeast Asian J. Trop. Med. Public Health23(Suppl. 2), 65–73 (1992).
   PubMedGoogle Scholar
• Taher A, Isma’eel H, Mehio G et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the mediterranean area and Iran. Thromb. Haemost.96(4), 488–491 (2006).
   PubMed Web of Science ®Google Scholar
• Karimi M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in β-thalassemia major (β-tm) and β-thalassemia intermedia (β-ti). Am. J. Hematol.83(1), 77–79 (2008).
   PubMed Web of Science ®Google Scholar
• Bush S, Mandel FS, Giardina PJ. Future orientation and life expectations of adolescents and young adults with thalassemia major. Ann. NY Acad. Sci.850, 361–369 (1998).
   PubMedGoogle Scholar
• Boulad F, Giardina P, Gillio A et al. Bone marrow transplantation for homozygous β-thalassemia. The Memorial Sloan–Kettering Cancer Center experience. Ann. NY Acad. Sci.850, 498–502 (1998).
   PubMedGoogle Scholar
• Giardini C, Lucarelli G. Bone marrow transplantation in the treatment of thalassemia. Curr. Opin. Hematol.1(2), 170–176 (1994).
   PubMedGoogle Scholar
• Thomas ED, Buckner CD, Sanders JE et al. Marrow transplantation for thalassaemia. Lancet2(8292), 227–229 (1982).
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. N. Engl. J. Med.322(7), 417–421 (1990).
   PubMed Web of Science ®Google Scholar
• La Nasa G, Argiolu F, Giardini C et al. Unrelated bone marrow transplantation for β-thalassemia patients: the experience of the Italian Bone Marrow transplant group. Ann. NY Acad. Sci.1054, 186–195 (2005).
   PubMed Web of Science ®Google Scholar
• Hongeng S, Pakakasama S, Chuansumrit A et al. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am. J. Hematol.82(12), 1095–1098 (2007).
   PubMedGoogle Scholar
• Sadelain M, Boulad F, Galanello R et al. Therapeutic options for patients with severe β-thalassemia: the need for globin gene therapy. Hum. Gene Ther.18(1), 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Szabolcs P, Haight A et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr. Transplant.11(6), 641–644 (2007).
   PubMed Web of Science ®Google Scholar
• Locatelli F, Rocha V, Reed W et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood101(6), 2137–2143 (2003).
   PubMed Web of Science ®Google Scholar
• Vanichsetakul P, Wacharaprechanont T, O-Charoen R, Seksarn P, Kupatawintu P. Umbilical cord blood transplantation in children with β-thalassemia diseases. J. Med. Assoc. Thai.87(Suppl. 2), S62–S67 (2004).
   Google Scholar
• Frangoul H, Wang L, Harrell FE Jr, Manes B, Calder C, Domm J. Unrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study. Bone Marrow Transplant. DOI: 10.1038/bmt.2009.137 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Oda M, Isoyama K, Ito E et al. Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Int. J. Hematol.89(3), 374–382 (2009).
   PubMed Web of Science ®Google Scholar
• Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev.23(5), 199–204 (2009).
   PubMed Web of Science ®Google Scholar
• Goldstein G, Toren A, Nagler A. Human umbilical cord blood biology, transplantation and plasticity. Curr. Med. Chem.13(11), 1249–1259 (2006).
   PubMedGoogle Scholar
• Ooi J. The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk. Lymphoma47(4), 599–602 (2006).
   PubMed Web of Science ®Google Scholar
• Misawa M, Kai S, Okada M et al. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow. Int. J. Hematol.83(1), 74–79 (2006).
   PubMedGoogle Scholar
• Petropoulos D, Chan KW. Umbilical cord blood transplantation. Curr. Oncol. Rep.7(6), 406–409 (2005).
   PubMedGoogle Scholar
• Luzzatto L. Genetics of red cells and susceptibility to malaria. Blood54(5), 961–976 (1979).
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Goodfellow P. Sickle cell anaemia. A simple disease with no cure. Nature337(6202), 17–18 (1989).
   PubMedGoogle Scholar
• Greaves DR, Fraser P, Vidal MA et al. A transgenic mouse model of sickle cell disorder. Nature343(6254), 183–185 (1990).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell126(4), 663–676 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5), 861–872 (2007).
   PubMed Web of Science ®Google Scholar
• Rivella S, May C, Chadburn A, Riviere I, Sadelain M. A novel murine model of cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood101(8), 2932–2939 (2003).
   PubMed Web of Science ®Google Scholar
• Imren S, Fabry ME, Westerman KA et al. High-level β-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J. Clin. Invest.114(7), 953–962 (2004).
   PubMed Web of Science ®Google Scholar
• Bank A, Dorazio R, Leboulch P. A Phase I/II clinical trial of β-globin gene therapy for β-thalassemia. Ann. NY Acad. Sci.1054, 308–316 (2005).
   PubMed Web of Science ®Google Scholar
• Malik P, Arumugam PI, Yee JK, Puthenveetil G. Successful correction of the human cooley’s anemia β-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. Ann. NY Acad. Sci.1054, 238–249 (2005).
   PubMed Web of Science ®Google Scholar
• Nishino T, Tubb J, Emery DW. Partial correction of murine β-thalassemia with a gretrovirus vector for human γ-globin. Blood Cells Mol. Dis.37(1), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Arumugam PI, Scholes J, Perelman N, Xia P, Yee JK, Malik P. Improved human β-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (chs4) insulator element. Mol. Ther.15(10), 1863–1871 (2007).
   PubMed Web of Science ®Google Scholar
• Hanawa H, Yamamoto M, Zhao H, Shimada T, Persons DA. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken β-globin locus hs4 insulator element. Mol. Ther.17(4), 667–674 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim YS, Larochelle A et al. Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. Blood113(22), 5434–5443 (2009).
   PubMedGoogle Scholar
• Zhao H, Pestina TI, Nasimuzzaman M, Mehta P, Hargrove PW, Persons DA. Amelioration of murine β-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both γ-globin and the MGMT drug-resistance gene. Blood113(23), 5747–5756 (2009).
   PubMed Web of Science ®Google Scholar
• May C, Rivella S, Callegari J et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature406(6791), 82–86 (2000).
   PubMed Web of Science ®Google Scholar
• May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene. Blood99(6), 1902–1908 (2002).
   PubMed Web of Science ®Google Scholar
• Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for β 0-thalassemia. Proc. Natl Acad. Sci. USA92(25), 11608–11612 (1995).
   PubMedGoogle Scholar
• Puthenveetil G, Scholes J, Carbonell D et al. Successful correction of the human β-thalassemia major phenotype using a lentiviral vector. Blood104(12), 3445–3453 (2004).
   PubMed Web of Science ®Google Scholar
• Crone TM, Pegg AE. A single amino acid change in human o6-alkylguanine-DNA alkyltransferase decreasing sensitivity to inactivation by o6-benzylguanine. Cancer Res.53(20), 4750–4753 (1993).
   PubMedGoogle Scholar
• Ragg S, Xu-Welliver M, Bailey J et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res.60(18), 5187–5195 (2000).
   PubMed Web of Science ®Google Scholar
• Gerson SL. Drug resistance gene transfer: stem cell protection and therapeutic efficacy. Exp. Hematol.28(12), 1315–1324 (2000).
   PubMedGoogle Scholar
• Imren S, Payen E, Westerman KA et al. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl Acad. Sci. USA99(22), 14380–14385 (2002).
   PubMed Web of Science ®Google Scholar
• Levasseur DN, Ryan TM, Pawlik KM, Townes TM. Correction of a mouse model of sickle cell disease: lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood102(13), 4312–4319 (2003).
   PubMed Web of Science ®Google Scholar
• Levasseur DN, Ryan TM, Reilly MP, McCune SL, Asakura T, Townes TM. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. J. Biol. Chem.279(26), 27518–27524 (2004).
   PubMed Web of Science ®Google Scholar
• Samakoglu S, Lisowski L, Budak-Alpdogan T et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat. Biotechnol.24(1), 89–94 (2006).
   PubMed Web of Science ®Google Scholar
• Miccio A, Cesari R, Lotti F et al.In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemia. Proc. Natl Acad. Sci. USA105(30), 10547–10552 (2008).
   PubMed Web of Science ®Google Scholar
• Maquat LE. Nonsense-mediated mRNA decay in mammals. J. Cell. Sci.118(Pt 9), 1773–1776 (2005).
   PubMed Web of Science ®Google Scholar
• Salvatori F, Cantale V, Breveglieri G et al. Development of k562 cell clones expressing β-globin mRNA carrying the β039 thalassemia mutation for the screening of correctors of stop codon mutations. Biotechnol. Appl. Biochem.54(1), 41–52 (2009).
   PubMedGoogle Scholar
• Salvatori F, Breveglieri G, Zuccato C et al. Production of β-globin and adult hemoglobin following g418 treatment of erythroid precursor cells from homozygous β039 thalassemia patients. Am. J. Hematol.84(11), 720–728 (2009).
   PubMed Web of Science ®Google Scholar
• Chui DH, Hardison R, Riemer C et al. An electronic database of human hemoglobin variants on the world wide web. Blood91(8), 2643–2644 (1998).
   PubMed Web of Science ®Google Scholar
• Giardine B, Van Baal S, Kaimakis P et al. Hbvar database of human hemoglobin variants and thalassemia mutations: 2007 update. Hum. Mutat.28(2), 206 (2007).
   PubMed Web of Science ®Google Scholar
• Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl Acad. Sci. USA90(18), 8673–8677 (1993).
   PubMed Web of Science ®Google Scholar
• Gorman L, Suter D, Emerick V, Schumperli D, Kole R. Stable alteration of pre-mRNA splicing patterns by modified u7 small nuclear RNAs. Proc. Natl Acad. Sci. USA95(9), 4929–4934 (1998).
   PubMed Web of Science ®Google Scholar
• Suter D, Tomasini R, Reber U, Gorman L, Kole R, Schumperli D. Double-target antisense u7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations. Hum. Mol. Genet.8(13), 2415–2423 (1999).
   PubMed Web of Science ®Google Scholar
• Lacerra G, Sierakowska H, Carestia C et al. Restoration of hemoglobin a synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl Acad. Sci. USA97(17), 9591–9596 (2000).
   PubMed Web of Science ®Google Scholar
• Suwanmanee T, Sierakowska H, Fucharoen S, Kole R. Repair of a splicing defect in erythroid cells from patients with β-thalassemia/hbe disorder. Mol. Ther.6(6), 718–726 (2002).
   PubMed Web of Science ®Google Scholar
• Suwanmanee T, Sierakowska H, Lacerra G et al. Restoration of human β-globin gene expression in murine and human ivs2–654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol. Pharmacol.62(3), 545–553 (2002).
   PubMed Web of Science ®Google Scholar
• Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest.112(4), 481–486 (2003).
   PubMed Web of Science ®Google Scholar
• Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R. High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood101(1), 104–111 (2003).
   PubMed Web of Science ®Google Scholar
• Chin JY, Kuan JY, Lonkar PS et al. Correction of a splice-site mutation in the β-globin gene stimulated by triplex-forming peptide nucleic acids. Proc. Natl Acad. Sci. USA105(36), 13514–13519 (2008).
   PubMed Web of Science ®Google Scholar
• Svasti S, Suwanmanee T, Fucharoen S et al. RNA repair restores hemoglobin expression in ivs2–654 thalassemic mice. Proc. Natl Acad. Sci. USA106(4), 1205–1210 (2009).
   PubMed Web of Science ®Google Scholar
• Sierakowska H, Sambade MJ, Agrawal S, Kole R. Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl Acad. Sci. USA93(23), 12840–12844 (1996).
   PubMed Web of Science ®Google Scholar
• Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat. Biotechnol.25(10), 1177–1181 (2007).
   PubMed Web of Science ®Google Scholar
• Hyun I, Hochedlinger K, Jaenisch R, Yamanaka S. New advances in IPS cell research do not obviate the need for human embryonic stem cells. Cell Stem Cell1(4), 367–368 (2007).
   PubMed Web of Science ®Google Scholar
• Hanna J, Wernig M, Markoulaki S et al. Treatment of sickle cell anemia mouse model with IPS cells generated from autologous skin. Science318(5858), 1920–1923 (2007).
   PubMed Web of Science ®Google Scholar
• Maherali N, Sridharan R, Xie W et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell1(1), 55–70 (2007).
   PubMed Web of Science ®Google Scholar
• Wernig M, Meissner A, Foreman R et al.In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature448(7151), 318–324 (2007).
   PubMed Web of Science ®Google Scholar
• Carey BW, Markoulaki S, Hanna J et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl Acad. Sci. USA106(1), 157–162 (2009).
   PubMed Web of Science ®Google Scholar
• Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science322(5903), 949–953 (2008).
   PubMed Web of Science ®Google Scholar
• Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science322(5903), 945–949 (2008).
   PubMed Web of Science ®Google Scholar
• Varas F, Stadtfeld M, De Andres-Aguayo L et al. Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions. Stem Cells27(2), 300–306 (2009).
   PubMedGoogle Scholar
• Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells27(3), 543–549 (2009).
   PubMed Web of Science ®Google Scholar
• Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science324(5928), 797–801 (2009).
   PubMed Web of Science ®Google Scholar
• Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol.6(10), e253 (2008).
   PubMed Web of Science ®Google Scholar
• Soldner F, Hockemeyer D, Beard C et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell136(5), 964–977 (2009).
   PubMed Web of Science ®Google Scholar
• Woltjen K, Michael IP, Mohseni P et al. Piggybac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature458(7239), 766–770 (2009).
   PubMed Web of Science ®Google Scholar
• Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature458(7239), 771–775 (2009).
   PubMed Web of Science ®Google Scholar
• Ye L, Chang JC, Lin C, Sun X, Yu J, Kan YW. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc. Natl Acad. Sci. USA106(24), 9826–9830 (2009).
   PubMed Web of Science ®Google Scholar
• Lyssiotis CA, Foreman RK, Staerk J et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of klf4. Proc. Natl Acad. Sci. USA106(22), 8912–8917 (2009).
   PubMed Web of Science ®Google Scholar